Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary S Tilbrook

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Memantine. MerzGavin J Kilpatrick, Gary S Tilbrook
Current Opinion in Anaesthesiology|July 11, 2006
Drug development in anaesthesia: industrial perspectiveGavin J Kilpatrick, Gary S Tilbrook
Anesthesia and Analgesia|January 19, 2012
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulationHugh R Wiltshire, Gavin J Kilpatrick, Gary S Tilbrook, et al.
The Journal of Pharmacy and Pharmacology|March 21, 2002
Synthesis and physicochemical assessment of novel 2-substituted 3-hydroxypyridin-4-ones, novel iron chelatorsMajid Y Moridani, Gary S Tilbrook, Hicham H Khodr, et al.
Anesthesia and Analgesia|December 23, 2011
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokineticsLaurie J Antonik, D Ronald Goldwater, Gavin J Kilpatrick, et al.
British Journal of Pharmacology|February 9, 2002
The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamusMary L Forsling, John K Fallon, Darshna Shah, et al.
Anesthesiology|June 23, 2007
CNS 7056: a novel ultra-short-acting BenzodiazepineGavin J Kilpatrick, Margaret S McIntyre, Richard F Cox, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Memantine. MerzGavin J Kilpatrick, Gary S Tilbrook
Current Opinion in Anaesthesiology|July 11, 2006
Drug development in anaesthesia: industrial perspectiveGavin J Kilpatrick, Gary S Tilbrook
Anesthesia and Analgesia|January 19, 2012
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulationHugh R Wiltshire, Gavin J Kilpatrick, Gary S Tilbrook, et al.
The Journal of Pharmacy and Pharmacology|March 21, 2002
Synthesis and physicochemical assessment of novel 2-substituted 3-hydroxypyridin-4-ones, novel iron chelatorsMajid Y Moridani, Gary S Tilbrook, Hicham H Khodr, et al.
Anesthesia and Analgesia|December 23, 2011
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokineticsLaurie J Antonik, D Ronald Goldwater, Gavin J Kilpatrick, et al.
British Journal of Pharmacology|February 9, 2002
The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamusMary L Forsling, John K Fallon, Darshna Shah, et al.
Anesthesiology|June 23, 2007
CNS 7056: a novel ultra-short-acting BenzodiazepineGavin J Kilpatrick, Margaret S McIntyre, Richard F Cox, et al.
Pageof 1